Literature DB >> 17230526

Effects of base excision repair gene polymorphisms on pancreatic cancer survival.

Donghui Li1, Yanan Li, Li Jiao, David Z Chang, Garth Beinart, Robert A Wolff, Douglas B Evans, Manal M Hassan, James L Abbruzzese.   

Abstract

To explore the association between single nucleotide polymorphisms of DNA repair genes and overall survival of patients with pancreatic cancer, we conducted a study in 378 cases of pancreatic adenocarcinoma who were treated at The University of Texas M. D. Anderson Cancer Center between February 1999 and October 2004 and were followed up to April 2006. Genotypes were determined using genomic DNA and the MassCode method. Overall survival was analyzed using the Kaplan-Meier plot, log-rank test and Cox regression. We observed a strong effect of the POLB A165G and T2133C genotypes on overall survival. The median survival time (MST) was 35.7 months for patients carrying at least 1 of the 2 homozygous variant POLB GG or CC genotypes, compared with 14.8 months for those carrying the AA/AG or TT/TC genotypes (p = 0.02, log rank test). The homozygous variants of hOGG1 G2657A, APEX1 D148E and XRCC1 R194W polymorphisms all showed a weak but significant effect on overall survival as demonstrated by either log rank test or multivariate COX regression after adjusting for other potential confounders. In combined genotype analysis, a predominant effect of the POLB homozygous variants on survival was observed. When POLB was not included in the model, a slightly better survival was observed among those carrying none of the adverse genotypes than those carrying at least one of the adverse genotypes. These observations suggest that polymorphisms of base excision repair genes significantly affect the clinical outcome of patients with pancreatic cancer. These observations need to be confirmed in a larger study of homogenous patient population. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17230526      PMCID: PMC1892183          DOI: 10.1002/ijc.22301

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  34 in total

1.  Incorporation of the guanosine triphosphate analogs 8-oxo-dGTP and 8-NH2-dGTP by reverse transcriptases and mammalian DNA polymerases.

Authors:  A S Kamath-Loeb; A Hizi; H Kasai; L A Loeb
Journal:  J Biol Chem       Date:  1997-02-28       Impact factor: 5.157

2.  Induction of a low level of microsatellite instability by overexpression of DNA polymerase Beta.

Authors:  Nazumi A Yamada; Rosann A Farber
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

Review 3.  Gemcitabine-mediated radiosensitization.

Authors:  T S Lawrence; A Eisbruch; D S Shewach
Journal:  Semin Oncol       Date:  1997-04       Impact factor: 4.929

Review 4.  The base excision repair pathway.

Authors:  E Seeberg; L Eide; M Bjørås
Journal:  Trends Biochem Sci       Date:  1995-10       Impact factor: 13.807

5.  Modulation of cellular response to cisplatin by a novel inhibitor of DNA polymerase beta.

Authors:  F Boudsocq; P Benaim; Y Canitrot; M Knibiehler; F Ausseil; J P Capp; A Bieth; C Long; B David; I Shevelev; E Frierich-Heinecken; U Hübscher; F Amalric; G Massiot; J S Hoffmann; C Cazaux
Journal:  Mol Pharmacol       Date:  2005-02-09       Impact factor: 4.436

6.  XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions.

Authors:  A E Vidal; S Boiteux; I D Hickson; J P Radicella
Journal:  EMBO J       Date:  2001-11-15       Impact factor: 11.598

Review 7.  Genetic testing for chemotherapy in non-small cell lung cancer.

Authors:  Rafael Rosell; Miquel Taron; Vicente Alberola; Bartomeu Massuti; Enriqueta Felip
Journal:  Lung Cancer       Date:  2003-08       Impact factor: 5.705

8.  Overexpression of DNA polymerase beta in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs.

Authors:  Y Canitrot; C Cazaux; M Fréchet; K Bouayadi; C Lesca; B Salles; J S Hoffmann
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

9.  Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients.

Authors:  Carlos Camps; Carmen Sarries; Bárbara Roig; José Javier Sanchez; Cristina Queralt; Eva Sancho; Natividad Martinez; Miguel Tarón; Rafael Rosell
Journal:  Clin Lung Cancer       Date:  2003-01       Impact factor: 4.785

Review 10.  Molecular predictors of response to chemotherapy in lung cancer.

Authors:  Rafael Rosell; Miquel Taron; Aurelio Ariza; Agusti Barnadas; Jose Luis Mate; Noemí Reguart; Mireia Margel; Enriqueta Felip; Pedro Méndez; Rosario García-Campelo
Journal:  Semin Oncol       Date:  2004-02       Impact factor: 4.929

View more
  21 in total

1.  A replication study and genome-wide scan of single-nucleotide polymorphisms associated with pancreatic cancer risk and overall survival.

Authors:  Jason A Willis; Sara H Olson; Irene Orlow; Semanti Mukherjee; Robert R McWilliams; Robert C Kurtz; Robert J Klein
Journal:  Clin Cancer Res       Date:  2012-06-04       Impact factor: 12.531

Review 2.  Targeting DNA polymerase ß for therapeutic intervention.

Authors:  Eva M Goellner; David Svilar; Karen H Almeida; Robert W Sobol
Journal:  Curr Mol Pharmacol       Date:  2012-01       Impact factor: 3.339

3.  Association between single-nucleotide polymorphisms of OGG1 gene and pancreatic cancer risk in Chinese Han population.

Authors:  Hongxu Chen; Bo Zhou; Xiang Lan; Dong Wei; Tao Yuan; Ping Chen
Journal:  Tumour Biol       Date:  2013-09-03

Review 4.  Base excision repair, aging and health span.

Authors:  Guogang Xu; Maryanne Herzig; Vladimir Rotrekl; Christi A Walter
Journal:  Mech Ageing Dev       Date:  2008-03-13       Impact factor: 5.432

5.  Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer.

Authors:  Hongmei Zeng; Herbert Yu; Lingeng Lu; Dhanpat Jain; Mark S Kidd; M Wasif Saif; Stephen J Chanock; Patricia Hartge; Harvey A Risch
Journal:  Pancreas       Date:  2011-07       Impact factor: 3.327

Review 6.  Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?

Authors:  Min Yuen Teo; Eileen M O'Reilly
Journal:  J Gastrointest Oncol       Date:  2016-10

7.  DNA repair gene polymorphisms and risk of pancreatic cancer.

Authors:  Donghui Li; Hideo Suzuki; Bingrong Liu; Jeffrey Morris; Jun Liu; Taro Okazaki; Yanan Li; Ping Chang; James L Abbruzzese
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

8.  Association between OGG1 gene single nucleotide polymorphisms and risk of pancreatic cancer in Chinese.

Authors:  Chengli Liu; Hui Huang; Cheng Wang; Yalin Kong; Hui Zhang; Hongyi Zhang
Journal:  Med Oncol       Date:  2014-06-17       Impact factor: 3.064

Review 9.  Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy.

Authors:  Lucy Gossage; Srinivasan Madhusudan
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

10.  Gastrointestinal hyperplasia with altered expression of DNA polymerase beta.

Authors:  Katsuhiko Yoshizawa; Elena Jelezcova; Ashley R Brown; Julie F Foley; Abraham Nyska; Xiangli Cui; Lorne J Hofseth; Robert M Maronpot; Samuel H Wilson; Antonia R Sepulveda; Robert W Sobol
Journal:  PLoS One       Date:  2009-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.